Neurology

MitoQ, an antioxidant drug under development by Antipodean Pharmaceuticals Inc, may have potential in treating multiple sclerosis in addition to other neurologic diseases.

Receptos is set to start phase III trials of a sphingosine-1–phosphate-1–receptor modulator codenamed RPC1063. Trial investigators are recruiting participants.

Amid conflicting evidence, Swedish researchers have found an association between multiple sclerosis (MS) and alcohol consumption, but the benefits of regular moderate alcohol intake in reducing the risk of MS may be attenuated by smoking.

The controversial chronic cerebrospinal venous insufficiency theory states that constricted vasculature is part of the pathophysiology of multiple sclerosis. A recent trial shows that the theory may be a scientific dead end.

Current Topics in Multiple Sclerosis features review articles on the diagnosis and treatment of multiple sclerosis.

An update to the Atlas of Multiple Sclerosis (MS) shows a modest increase in the number of patients with MS and the prevalence of MS between 2008 and 2013. The report also highlights disparities in access to treatment between high- and low-income countries.

A Novartis-sponsored study found better continuation rates and higher adherence in participants receiving oral disease-modifying therapy for multiple sclerosis.

Specialty medications on the path to approval include 2 new hepatitis drugs.

Understanding stroke is the first step in knowing how to prevent it.

Understanding stroke is the first step in knowing how to prevent it.

Use of tumor necrosis factor–alpha inhibitors was recently linked to the reactivation of ancillary neurologic adverse events.

Negative findings were reported for both clinical and imaging measures in a Phase II randomized trial of riluzole in comparison to placebo in patients with very early multiple sclerosis (MS).

Multiple sclerosis treatment options have expanded dramatically over the past several years. In addition to subcutaneous and intravenous medications, there are now 3 disease-modifying oral therapies available in the United States.

A study compared historical and contemporary multiple sclerosis cases to determine how first-generation disease-modifying drugs affected disease progression.

An assessment of costs and specialty drug use within 4 chronic conditions found specialty drugs contribute to overall costs for insurance plan members.

A pair of recent studies finds that those with a history of cancer have up to a 51% reduced risk of developing Alzheimer's disease.

Patients who continued taking simvastatin and atorvastatin had significantly reduced risk of developing Parkinson's disease compared with those who discontinued statin therapy.

The diagnosis of multiple sclerosis is not occurring early enough, despite recent advances in diagnostic tools and imaging.

Tecfidera (dimethyl fumarate) has been approved by the FDA for the treatment of relapsing forms of multiple sclerosis.

A survey of US neurologists found that a significant minority is unaware of FDA drug safety updates and many who are aware of the updates fail to act on them.